Hatteras Venture Partners I (HVP I) is a $3 million venture capital fund focused on pre-seed and seed investments in human medicine and information technology. HVP I was launched in late 2000.
Based upon technology from UNC and East Carolina University that was funded by over a decade of Department of Navy funding, Entegrion is developing hemostatic technologies for wound management, tissue repair, and control of hemorrhage. The company’s lead product (Stasilon-FR, formerly AlphaBandage) is FDA approved for use as an external hemostatic bandage.
Noverant provides web-based Learning Management Systems for Training, Compliance, and Auditing for small and medium-sized businesses. Our comprehensive, user-friendly software and services provide low-cost and company-wide solutions resulting in 100% of a company’s training requirements — conforming internally and externally with any and all Regulatory Agencies.
Respirics is a respiratory drug company focused on development and delivery of powdered formulations of important respiratory medications. The company’s Accu-Breathe delivery device is the first of its kind to enable the dispensing of powdered drug as the patient inhales, improving patient compliance and therapy. Respiric’s lead program is Accu-30 Albuterol, the first powdered form of albuterol in clinical development in the United States.
PhaseBio is a biopharmaceutical company applying a flexible new platform for biological drugs (peptides and proteins) based on the use of elastin-like polypeptides (ELP’s). PhaseBio’s engineered proteins and peptides have improved manufacturing, pharmacokinetic, and pharmacodynamic properties. The company’s lead programs in phenylketonuria (PKU), diabetes, and respiratory diseases are entering clinical trials.
Synthematix (now Symyx Technologies, Inc. — SMMX) is focused on developing and deploying software solutions for discovery and medicinal chemists. In April 2005, Synthematix was acquired by Symyx Technologies.